TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02704117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magentic Stimulation
Description: This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
Study: NCT01655615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventure programme
Description: The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
Study: NCT02562053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Women will receive oral fluoxetine 20 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Women will receive oral fluoxetine 20 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptives
Description: women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
Study: NCT03128606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 single dose
Description: GLPG3067 oral suspension, single ascending doses, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Placebo, oral suspension, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 multiple dose
Description: GLPG3067 oral suspension, multiple ascending doses, daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple dose
Description: Placebo, oral suspension, daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 oral suspension
Description: GLPG3067 oral suspension, single dose, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 oral tablet
Description: GLPG3067 oral tablet, single dose, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 oral tablet
Description: GLPG3067 oral tablet, single dose, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 oral tablet
Description: GLPG3067 oral tablet, single dose, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 oral tablet
Description: GLPG3067 oral tablet, single dose, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067/GLPG2222 multiple dose
Description: GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
Study: NCT04182399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide Capsules
Description: anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zonisamide Capsules
Description: anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
Study: NCT02549027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
Study: NCT04604886

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising
Description: Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dobutamine stress test
Description: Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
Study: NCT03696238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500mg of Aronox® >40% polyphenol aronia extract
Description: Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
Study: NCT01837446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% morphine solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium aluminum hydroxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% viscous lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Study: NCT02748044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CC-Cruiser
Description: An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
Study: NCT04346173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: furlow z plasty with buccinator myomucosal flap
Description: using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
Study: NCT01396824

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04380194

Intervention type: DIAGNOSTIC_TEST
Intervention: nano-composite screening
Description: Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses

Intervention type: DIAGNOSTIC_TEST
Intervention: nano-composite screening
Description: Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
Study: NCT00616018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 4 g/day for 10 consecutive days
Study: NCT03128606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG3067/GLPG2222 Placebo multiple dose
Description: GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067/GLPG2222/GLPG2737 multiple dose
Description: GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose
Description: GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
Study: NCT01203111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
Study: NCT02628366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Dialysate Temperature
Description: Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
Study: NCT01370772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: * Cycle 1 Rituximab : 375 mg/m² i.v on day 1~* Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: * Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~* Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: •FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: •FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
Study: NCT02639754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Leader Endorsement
Description: Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling
Description: At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
Study: NCT02332694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
Study: NCT00683774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diazoxide
Description: 100mg orally three times per day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diazoxide
Description: 100mg orally three times per day for 10 days
Study: NCT01487928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human Milk Cream
Description: If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
Study: NCT01646346

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4D Conformal Image-Guided Partial Breast RT
Description: External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
Study: NCT03731910

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
Study: NCT04496388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: different type of exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: different type of exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: different type of exercise
Study: NCT02562053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1
Description: Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive a daily oral placebo similar to fluoxetine
Study: NCT04203238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Meat High Potato Diet
Description: The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Meat High Pulses Diet
Description: The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses.
Study: NCT02792608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Therapy
Description: MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
Study: NCT04448288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Static stretchings were performed by subjects that involved varied repetitions of 30-s static-stretches and 20-s relax period.
Study: NCT04496388

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No exercise intervention
Description: No exercise intervention
Study: NCT02631668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferrous succinate and vitamin C
Description: As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous succinate
Description: As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
Study: NCT03323931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (2) robot--enhanced intervention
Description: The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (1) discrete trial training / cognitive-behavior therapy
Description: The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
Study: NCT02631668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous succinate
Description: As another active comparator, patients take the tablets of ferrous succinate with double dosage
Study: NCT04023175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine preoperative counseling
Description: The telemedicine visit will be completed using an Atrium Health approved virtual visit platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In office preoperative counseling
Description: This includes our standard preoperative counseling located at the Women's Center for Pelvic Health
Study: NCT01697891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Codetron ALTENS
Description: ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
Study: NCT00756574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical mask
Description: Surgical mask worn for patients with febrile respiratory illness
Study: NCT02692976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mDC vaccination
Description: Intranodal mDC vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pDC vaccination
Description: Intranodal pDC vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mDC and pDC vaccination
Description: Intranodal mDC/pDC vaccination
Study: NCT00756574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N95 mask
Description: N95 mask worn for patients with febrile respiratory illness
Study: NCT04012762

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration training
Description: Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration training
Description: Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
Study: NCT03626844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lysis of Placenta after 15 minutes (Intervention)
Description: Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lysis of Placenta after 30 minutes (Control)
Description: Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
Study: NCT05617248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy App
Description: The training starts with a psychoeducational video and instructions to define two autobiographical self-efficacy The individuals will then receive three self-efficacy trainings per day based on their autobiographical memories and combined with a slow breathing exercise. Additionally, they will receive 10 daily EMA questionnaires on mood, social contacts, and virtual context.
Study: NCT03697863

Intervention type: PROCEDURE
Intervention: Noninvasive Respiratory Support
Description: Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist

Intervention type: PROCEDURE
Intervention: Noninvasive Respiratory Support
Description: Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
Study: NCT00700297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 100 mg Colchicine per day for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet placebo per day for 4 months
Study: NCT04569864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion
Description: Hypothermic circulatory arrest provides protection to cerebral and visceral organs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion
Description: Hypothermic circulatory arrest provides protection to cerebral and visceral organs.
Study: NCT02723916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ezParent Program
Description: Tablet-based behavioral parent training program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health-e Kids Control App
Description: Tablet based health promotion information App
Study: NCT02835313

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAST alone
Description: Subjects participate in fast walking training 3x/week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAST+SAM
Description: Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAM alone
Description: Subjects participate in a step activity monitoring program 3x/week for 12 weeks